AR036079A1 - Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados - Google Patents
Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionadosInfo
- Publication number
- AR036079A1 AR036079A1 ARP020102075A ARP020102075A AR036079A1 AR 036079 A1 AR036079 A1 AR 036079A1 AR P020102075 A ARP020102075 A AR P020102075A AR P020102075 A ARP020102075 A AR P020102075A AR 036079 A1 AR036079 A1 AR 036079A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- compounds
- halo
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
Abstract
Se describen y reivindican compuestos de N-[benzoil]-fenilsulfonamidas de fórmula (1) donde X es O o NH; R1 es hidrógeno, halo, alquilo C1-6, alcoxi C1-4, alquiltio C1-4, CF3, OCF3, SCF3, (alcoxi C1-4)carbonilo, nitro, azido, O(SO2)CH3, N(CH3)2, hidroxi, fenilo, fenilo sustituido, piridinilo, tienilo, furilo, quinolinilo, o triazolilo; R2 es hidrógeno, halo, ciano, CF3, alquilo C1-6 (alcoxi C1-4)carbonilo, alcoxi C1-4, fenilo o quinolinilo; R2a es hidrógeno o alcoxi C1-4; R2b es hidrógeno, halo, alquilo C1-6, con la condición de que al menos uno de R2a y R2b sea hidrógeno; R3 es hidrógeno, halo, alquilo C1-6, CF3 o nitro; R3a es hidrógeno, halo o alquilo C1-6, con la condición de que cuando R3a es alquilo C1-6, R3 sea hidrógeno y R4 sea halo, y R4 es halo, alquilo C1-6 o CF3, con la condición de que solo uno de R3 y R4 puede ser alquilo C1-6 y con la condición de que cuando R4 es halo o alquilo C1-6, sólo uno de R3 y R3a sea hidrógeno; o una sal de adición de base farmacéuticamente aceptable del mismo, con la condición de que: a) cuando tanto R3 como R4 son cloro y R2 es hidrógeno, R1 sea bromo, yodo, alcoxi C1-4, alquiltio C1-4, CF3, OCF3, nitro, azido, O(SO2)CH3, N(CH3)2, hidroxi, fenilo, fenilo sustituido, piridinilo, tienilo, furilo o triazolilo y b) cuanto tanto R3 como R4 son cloro y R1 es hidrógeno, R2 sea bromo, fluoro, CF3, alquilo C1-6, alcoxi C1-4, fenilo o quinolinilo. Dichos compuestos son de aplicación en la manufactura de composiciones farmacéuticas-medicamentos- adaptadas para el tratamiento de neoplasmas susceptibles, mediante la administración de cantidades efectivas de los compuestos mencionados. Se describen y reivindican además, los objetos restantes mencionados en el título.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29635001P | 2001-06-06 | 2001-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036079A1 true AR036079A1 (es) | 2004-08-11 |
Family
ID=23141662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102075A AR036079A1 (es) | 2001-06-06 | 2002-06-04 | Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US7183320B2 (es) |
| EP (1) | EP1401806B1 (es) |
| JP (1) | JP4167173B2 (es) |
| KR (1) | KR100880760B1 (es) |
| CN (1) | CN100475787C (es) |
| AR (1) | AR036079A1 (es) |
| AT (1) | ATE335722T1 (es) |
| AU (1) | AU2002259204B2 (es) |
| BR (1) | BR0210078A (es) |
| CA (1) | CA2446719A1 (es) |
| CR (1) | CR7182A (es) |
| CY (1) | CY1105386T1 (es) |
| CZ (1) | CZ20033296A3 (es) |
| DE (1) | DE60213810T2 (es) |
| DK (1) | DK1401806T3 (es) |
| EA (1) | EA005810B1 (es) |
| EC (1) | ECSP034874A (es) |
| EG (1) | EG24356A (es) |
| ES (1) | ES2269688T3 (es) |
| HK (1) | HK1064360A1 (es) |
| HR (1) | HRP20031000A2 (es) |
| HU (1) | HUP0400114A3 (es) |
| IL (1) | IL158985A0 (es) |
| MX (1) | MXPA03011197A (es) |
| MY (1) | MY136855A (es) |
| NO (1) | NO20035366L (es) |
| NZ (1) | NZ529098A (es) |
| PE (1) | PE20030199A1 (es) |
| PL (1) | PL367188A1 (es) |
| PT (1) | PT1401806E (es) |
| SK (1) | SK14642003A3 (es) |
| SV (1) | SV2003001076A (es) |
| TW (1) | TWI266761B (es) |
| UA (1) | UA74889C2 (es) |
| WO (1) | WO2002098848A1 (es) |
| ZA (1) | ZA200308644B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375978T1 (de) * | 2002-11-22 | 2007-11-15 | Lilly Co Eli | Benzoylsulfonamide als antitumor-mittel |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| JP5284641B2 (ja) * | 2004-05-26 | 2013-09-11 | アボット・ラボラトリーズ | Ｎ−スルホニルカルボキシイミドアミドアポトーシス促進剤 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| JP5134247B2 (ja) * | 2004-09-13 | 2013-01-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| WO2006030941A1 (ja) * | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| WO2006090928A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の血管新生阻害物質との新規併用 |
| CN101163468A (zh) * | 2005-02-28 | 2008-04-16 | 卫材R&D管理有限公司 | 磺酰胺化合物的新联合用途 |
| WO2006090921A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物のリンパ球活性化抑制作用 |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US7208526B2 (en) * | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
| US7208506B2 (en) | 2005-07-07 | 2007-04-24 | Hoffmann-La Roche Inc. | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents |
| US7625896B2 (en) * | 2005-11-25 | 2009-12-01 | Hoffman-La Roche Inc. | Pyridylsulfonamide derivatives |
| EP2015070A4 (en) | 2006-04-20 | 2010-04-21 | Eisai R&D Man Co Ltd | NEW MARKER AGAINST SENSITIVITY TO A SULFONAMIDE COMPOUND |
| EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| US7939532B2 (en) | 2006-10-26 | 2011-05-10 | Hoffmann-La Roche Inc. | Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents |
| CN101675033A (zh) | 2007-05-16 | 2010-03-17 | 霍夫曼-拉罗奇有限公司 | 芳基吡啶基磺酰胺衍生物，它们的制备和作为药剂的应用 |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2539587C2 (ru) * | 2009-01-19 | 2015-01-20 | Эббви Инк. | Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| JP2012136435A (ja) * | 2009-03-30 | 2012-07-19 | Eisai R & D Management Co Ltd | 腫瘍組織の感受性を検査する方法 |
| KR200457823Y1 (ko) * | 2009-05-08 | 2012-01-05 | 황정용 | 쭈꾸미 포획용 어구 |
| TWI537269B (zh) | 2009-05-26 | 2016-06-11 | 艾伯維巴哈馬有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑 |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2568611C2 (ru) * | 2010-03-25 | 2015-11-20 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012071374A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
| US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| CN103159649B (zh) * | 2011-12-19 | 2016-03-09 | 天津市国际生物医药联合研究院 | 磺酰胺类化合物的制备及其应用 |
| CN103159650B (zh) * | 2011-12-19 | 2016-04-20 | 天津市国际生物医药联合研究院 | 芳香杂环磺酰胺类化合物的制备及其应用 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN105712925B (zh) * | 2014-12-05 | 2019-01-04 | 沈阳中化农药化工研发有限公司 | 一种取代的磺酰胺基(硫代)羰基化合物及其用途 |
| WO2016129983A1 (en) | 2015-02-13 | 2016-08-18 | Latvian Institute Of Organic Synthesis | Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors |
| CN105753748B (zh) * | 2016-02-15 | 2018-05-29 | 南京励合化学新材料有限公司 | 一种医药中间体磺酰类化合物的合成方法 |
| GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
| WO2018237163A1 (en) * | 2017-06-23 | 2018-12-27 | Roman Manetsch | 5-AMINOLEVULINATE SYNTHASE INHIBITORS AND METHODS OF USE |
| WO2019133797A1 (en) * | 2017-12-29 | 2019-07-04 | Wu, Lester J. | Benzenesulfonamide derivatives and method for modulating lipid raft |
| CN114790149A (zh) * | 2021-01-26 | 2022-07-26 | 江苏中旗科技股份有限公司 | 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4157257A (en) | 1976-10-01 | 1979-06-05 | Utsunomiya University | Benzenesulfonamide derivatives |
| US4266078A (en) * | 1979-04-20 | 1981-05-05 | Stauffer Chemical Company | N-Acylsulfonamide herbicidal antidotes |
| US4347380A (en) * | 1979-04-20 | 1982-08-31 | Stauffer Chemical Company | N-Acylsulfonamide herbicidal antidotes |
| US4433997A (en) * | 1979-04-20 | 1984-02-28 | Stauffer Chemical Co | N-Acylsulfonamide herbicidal antidotes |
| US4495365A (en) * | 1980-11-21 | 1985-01-22 | Stauffer Chemical Co. | N-Acylsulfonamide herbicidal antidotes |
| US4845128A (en) * | 1984-06-27 | 1989-07-04 | Eli Lilly And Company | N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides |
| US5110830A (en) * | 1984-06-27 | 1992-05-05 | Eli Lilly And Company | Benzenesulfonamides treatment of tumors susceptible to |
| JP2679498B2 (ja) * | 1991-12-25 | 1997-11-19 | 王子製紙株式会社 | 感熱記録体 |
| CA2110524A1 (en) * | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
| JPH0747772A (ja) * | 1993-08-05 | 1995-02-21 | New Oji Paper Co Ltd | 感熱記録体 |
| WO1996036611A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
| ES2193615T3 (es) * | 1995-10-25 | 2003-11-01 | Senju Pharma Co | .nhibidor de la angiogenesis. |
| US5929097A (en) | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| EP1150687A2 (en) * | 1999-02-12 | 2001-11-07 | Cellpath, Inc. | Methods for anti-tumor therapy |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
-
2002
- 2002-05-24 DE DE60213810T patent/DE60213810T2/de not_active Expired - Fee Related
- 2002-05-24 ES ES02729196T patent/ES2269688T3/es not_active Expired - Lifetime
- 2002-05-24 KR KR1020037015958A patent/KR100880760B1/ko not_active IP Right Cessation
- 2002-05-24 AT AT02729196T patent/ATE335722T1/de not_active IP Right Cessation
- 2002-05-24 MX MXPA03011197A patent/MXPA03011197A/es active IP Right Grant
- 2002-05-24 WO PCT/US2002/015142 patent/WO2002098848A1/en active IP Right Grant
- 2002-05-24 CN CNB028115104A patent/CN100475787C/zh not_active Expired - Fee Related
- 2002-05-24 PL PL02367188A patent/PL367188A1/xx not_active Application Discontinuation
- 2002-05-24 CZ CZ20033296A patent/CZ20033296A3/cs unknown
- 2002-05-24 SK SK1464-2003A patent/SK14642003A3/sk unknown
- 2002-05-24 NZ NZ529098A patent/NZ529098A/en unknown
- 2002-05-24 AU AU2002259204A patent/AU2002259204B2/en not_active Ceased
- 2002-05-24 DK DK02729196T patent/DK1401806T3/da active
- 2002-05-24 EP EP02729196A patent/EP1401806B1/en not_active Expired - Lifetime
- 2002-05-24 EA EA200400006A patent/EA005810B1/ru not_active IP Right Cessation
- 2002-05-24 US US10/478,389 patent/US7183320B2/en not_active Expired - Fee Related
- 2002-05-24 CA CA002446719A patent/CA2446719A1/en not_active Abandoned
- 2002-05-24 PT PT02729196T patent/PT1401806E/pt unknown
- 2002-05-24 HU HU0400114A patent/HUP0400114A3/hu unknown
- 2002-05-24 JP JP2003501838A patent/JP4167173B2/ja not_active Expired - Fee Related
- 2002-05-24 UA UA20031211105A patent/UA74889C2/uk unknown
- 2002-05-24 IL IL15898502A patent/IL158985A0/xx unknown
- 2002-05-24 BR BR0210078-9A patent/BR0210078A/pt not_active IP Right Cessation
- 2002-06-03 TW TWPHENYLSULA patent/TWI266761B/zh not_active IP Right Cessation
- 2002-06-04 EG EG2002060594A patent/EG24356A/xx active
- 2002-06-04 AR ARP020102075A patent/AR036079A1/es unknown
- 2002-06-05 SV SV2002001076A patent/SV2003001076A/es not_active Application Discontinuation
- 2002-06-05 MY MYPI20022075A patent/MY136855A/en unknown
- 2002-06-07 PE PE2002000494A patent/PE20030199A1/es not_active Application Discontinuation
-
2003
- 2003-11-05 ZA ZA200308644A patent/ZA200308644B/en unknown
- 2003-12-02 EC EC2003004874A patent/ECSP034874A/es unknown
- 2003-12-02 NO NO20035366A patent/NO20035366L/no not_active Application Discontinuation
- 2003-12-03 HR HR20031000A patent/HRP20031000A2/xx not_active Application Discontinuation
- 2003-12-05 CR CR7182A patent/CR7182A/es unknown
-
2004
- 2004-09-14 HK HK04107015A patent/HK1064360A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101396T patent/CY1105386T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036079A1 (es) | Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
| SE0300956D0 (sv) | Stabilisatorblandningar | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| BRPI0014869B8 (pt) | prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
| CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
| NO20055655L (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
| DE60114994D1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
| NO20052529L (no) | Forbindelse og sammensetning, og anvendelse av samme | |
| AR004002A1 (es) | Composicion util especialmente para el tratamiento y la proteccion de los animales domesticos infestados o susceptibles de ser infestados por parasitos | |
| AR058720A1 (es) | Derivados 2-feniletilamino y composicion farmaceutica | |
| DK1735296T3 (da) | Materialer og fremgangsmåder til behandling af koagulationslidelser | |
| AR032781A1 (es) | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen | |
| PE20071132A1 (es) | Compuestos macrociclicos como inhibidores del factor viia | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
| DK1210320T3 (da) | Aminobenzofenoner som inhibitorer for IL-1beta og TNF-alfa | |
| DE60014394D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| KR920002579A (ko) | 종양치료 조성물 및 치료방법 | |
| CO5080727A1 (es) | Ligandos azabiciclicos de receptores 5 ht1 | |
| EA200600570A1 (ru) | Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |